• 1
    Abdel-Wahab M. Schistosomiasis in Egypt. Boca Raton, Florida: CRC Press, 1982.
  • 2
    Abdel-Wahab MF, Strickland GT, El-Sahly A, Ahmed L, Zakaria S, El Kady N, et al. Schistosomiasis mansoni in an Egyptian village in the Nile Delta. Am J Trop Med Hyg 1980; 29: 868874.
  • 3
    Strickland GT, Ramirez BL. Schistosomiasis. In: StricklandGT, ed. Hunter's Tropical Medicine and Emerging Infectious Diseases. Eighth ed. Philadelphia: Saunders, 2000: 804831.
  • 4
    Scott J. The incidence and distribution of human schistosomiasis in Egypt. Am J Trop Med Hyg 1937; 25: 566614.
  • 5
    Abdel-Wahab MF, Strickland GT, El-Sahly A, El-Kady N, Zakaria S, Ahmed L. Changing pattern of schistosomiasis in Egypt 1935–79. Lancet 1979; 2: 242244.
  • 6
    Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887891.
  • 7
    El-Khoby T, Galal N, Fenwick A, Barakat R, El-Hawey A, Nooman Z, et al. The epidemiology of schistosomiasis in Egypt: summary findings in nine governorates. Am J Trop Med Hyg 2000; 62: 8899.
  • 8
    Abdel-Wahab MF, Yosery A, Narooz S, Esmat G, el Hak S, Nasif S, et al. Is Schistosoma mansoni replacing Schistosoma haematobium in the Fayoum? Am J Trop Med Hyg 1993; 49: 697700.
  • 9
    Abdel-Wahab MF, Esmat G, Ramzy I, Narooz S, Medhat E, Ibrahim M, et al. The epidemiology of schistosomiasis in Egypt: Fayoum Governorate. Am J Trop Med Hyg 2000; 62: 5564.
  • 10
    Gabr NS, Hammad TA, Orieby A, Shawky E, Khattab MA, Strickland GT. The epidemiology of schistosomiasis in Egypt: Minya Governorate. Am J Trop Med Hyg 2000; 62: 6572.
  • 11
    Abdel-Wahab MF, Esmat G, Milad M, Abdel-Razek S, Strickland GT. Characteristic sonographic pattern of schistosomal hepatic fibrosis. Am J Trop Med Hyg 1989; 40: 7276.
  • 12
    Abdel-Wahab MF, Esmat G, Farrag A, el-Boraey YA, Strickland GT. Grading of hepatic schistosomiasis by the use of ultrasonography. Am J Trop Med Hyg 1992; 46: 403408.
  • 13
    Fenwick A, Savioli L, Engels D, Robert Bergquist N, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 2003; 19: 509515.
  • 14
    Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg 1994; 51: 563567.
  • 15
    Darwish MA, Faris R, Clemens JD, Rao MR, Edelman R. High seroprevalence of hepatitis A, B, C, and E viruses in residents in an Egyptian village in The Nile Delta: a pilot study. Am J Trop Med Hyg 1996; 54: 554558.
  • 16
    Arthur RR, Hassan NF, Abdallah MY, el-Sharkawy MS, Saad MD, Hackbart BG, et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg 1997; 91: 271274.
  • 17
    Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. HEPATOLOGY 2000; 32: 111115.
  • 18
    Nafeh MA, Medhat A, Shehata M, Mikhail NN, Swifee Y, Abdel-Hamid M, et al. Hepatitis C in a community in Upper Egypt: I. Cross-sectional survey. Am J Trop Med Hyg 2000; 63: 236241.
  • 19
    El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy, H, El-Tawil A, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.. Am J Gastroenterol 2005; 100; 24472452.
    Direct Link:
  • 20
    Kamal SM, El-Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon (alpha)-2b and ribavirin therapy in chronic hepatitis C genotype 4; impact of treatment duration and viral kinetics on sustained viral response. Gut 2005; 54: 858866.
  • 21
    Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. HEPATOLOGY 2001; 33: 248253.
  • 22
    Medhat A, Shehata M, Magder LS, Mikhail N, Abdel-Baki L, Nafeh M, et al. Hepatitis c in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg 2002; 66: 633638.
  • 23
    Magder LS, Fix AD, Mikhail NN, Mohamed MK, Abdel-Hamid M, Abdel-Aziz F, et al. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. Int J Epidemiol 2005; 34: 160165.
  • 24
    Mohamed MK, Abdel-Hamid M, Mikhail NN, Abdel-Aziz F, Medhat A, Magder LS, et al. Intrafamilial transmission of hepatitis C in Egypt. HEPATOLOGY 2005; 42: 683687.
  • 25
    Waked IA, Saleh SM, Moustafa MS, Raouf AA, Thomas DL, Strickland GT. High prevalence of hepatitis C in Egyptian patients with chronic liver disease. Gut 1995; 37: 105107.
  • 26
    Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg 2002; 67: 436442.
  • 27
    Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997; 26: 236243.
  • 28
    Darwish MA, Faris R, Darwish N, Shouman A, Gadallah M, El-Sharkawy MS, et al. Hepatitis C and cirrhotic liver disease in the Nile delta of Egypt: a community-based study. Am J Trop Med Hyg 2001; 64: 147153.
  • 29
    Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001; 33: 123126.
  • 30
    Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, et al. Association of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005; 208: 329339.
  • 31
    Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002; 35: 266269.
  • 32
    Abdel-Wahab M, el-Enein AA, Abou-Zeid M, el-Fiky A, Abdallah T, Fawzy M, et al. Hepatocellular carcinoma in Mansoura-Egypt: experience of 385 patients at a single center. Hepatogastroenterology 2000; 47: 663668.
  • 33
    Cowgill KD, Loffredo CA, Eissa SA, Mokhtar N, Abdel-Hamid M, Fahmy A, et al. Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol 2004; 33: 10341039.
  • 34
    Strickland GT. Gastrointestinal manifestations of schistosomiasis. Gut 1994; 35: 13341337.
  • 35
    Lyra LG, Reboucas G, Andrade ZA. Hepatitis B surface antigen carrier state in hepatosplenic schistosomiasis. Gastroenterology 1976; 71: 641645.
  • 36
    Domingo EO, Lingao AL, Tiu E, Lao JY, Olveda RM. HBV exposure and HBsAg positivity rates in schistosomiasis japonica: study in a Philippine community endemic for both infections. Southeast Asian J Trop Med Public Health 1983; 14: 456462.
  • 37
    Bassily S, Dunn MA, Farid Z, Kilpatrick ME, El-Masry NA, Kamel IA, et al. Chronic hepatitis B in patients with schistosomiasis mansoni. J Trop Med Hyg 1983; 86: 6771.
  • 38
    Madwar MA, el Tahawy M, Strickland GT. The relationship between uncomplicated schistosomiasis and hepatitis B infection. Trans R Soc Trop Med Hyg 1989; 83: 233236.
  • 39
    Ghaffar YA, Fattah SA, Kamel M, Badr RM, Mahomed FF, Strickland GT. The impact of endemic schistosomiasis on acute viral hepatitis. Am J Trop Med Hyg 1991; 45: 743750.
  • 40
    Kamal S, Madwar M, Bianchi L, Tawil AE, Fawzy R, Peters T, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000; 20: 281289.
  • 41
    Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000; 32: 172174.
  • 42
    Kullberg MC, Pearce EJ, Hieny SE, Sher A, Berzofsky JA. Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J Immunol 1992; 148: 32643270.
  • 43
    Actor JK, Shirai M, Kullberg MC, Buller RM, Sher A, Berzofsky JA. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci U S A 1993; 90: 948952.
  • 44
    Actor JK, Marshall MA, Eltoum IA, Buller RM, Berzofsky JA, Sher A. Increased susceptibility of mice infected with Schistosoma mansoni to recombinant vaccinia virus: association of viral persistence with egg granuloma formation. Eur J Immunol 1994; 24: 30503056.
  • 45
    Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 14991512.
  • 46
    Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 13951406.
  • 47
    Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001; 121: 646656.
  • 48
    Kamal SM, Bianchi L, Al Tawil A, Koziel M, El Sayed Khalifa K, Peter T, et al. Specific cellular immune response and cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. J Infect Dis 2001; 184: 972982.
  • 49
    Kamal SM, Graham CS, He Q, Bianchi L, Tawil AA, Rasenack JW, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004; 189: 11401150.
  • 50
    Farid A, Al-Sherbiny M, Osman A, Mohamed N, Saad A, Shata MT, et al. Schistosoma infection inhibits cellular immune responses to core HCV peptides. Parasite Immunol 2005; 27: 189196.